BIOPATH - Key Persons
Ms. Sherwood was appointed to the Board on March 31, 2022. Since January 2017, Ms. Sherwood has been the owner of Scienta Communications, LLC, an independent communications consultancy established in 2010 to provide strategic public relations and corporate communications counsel to pre-commercial, public and private life sciences companies. In this capacity, she has provided strategic communications and crisis management counsel to biotechnology and medical device executives. On a day-to-day basis, she provides tactical support including development of materials and coordination of events, conference calls and webcasts, supports client milestones with media outreach and provides strategic counsel to enhance the company's perception on Wall Street and in industry.
Earlier in her career, Ms. Sherwood managed corporate communications for The Liposome Company. During the subsequent decade, she worked at a series of global and boutique public and investor relations agencies where she provided support for companies pursuing a variety of indications including oncology. Through these combined experiences, Ms. Sherwood developed a general knowledge of the research and development process, and an understanding of the potential of delivery technologies to enhance oncology drug development.
Job Titles:
- Senior Vice President of Finance
- Senior Vice President of Finance, Accounting & Administration
Anthony Price serves as Senior Vice President of Finance, Accounting & Administration. He joined Bio-Path in May 2014 and has 15 years of experience in the healthcare field. From October 2006 through April 2014, he held positions in finance at Lexicon Pharmaceuticals, Inc., most recently as Associate Director of Finance and Accounting. From 1993 to 2006, Mr. Price served in a variety of financial and accounting management positions for Building Materials Holding Corporation. Mr. Price holds a Bachelor of Science in business administration - finance from California State University, Fresno and a Master of Business Administration from Colorado State University.
Dr. Hooper is a professor of cancer biology and neurological surgery and the section chief for translational research in the department of neurological surgery's tumor division at Thomas Jefferson University. He has made important contributions to the understanding of immunity, particularly with respect to therapeutic and pathological mechanisms acting in central nervous system tissues, with over 140 peer-reviewed, full-length publications. Dr. Hooper's work has led to novel immune therapies for rabies infection, neuroinflammation, and cancer with 10 issued U.S. patents and 19 international patents that have been licensed to five companies in the U.S. and abroad. He is the founding president of the Jefferson Chapter of the National Academy of Inventors and a fellow of the National Academy of Inventors. He is a co-founder of Imvax Inc., a startup company that has licensed Jefferson systemic cancer immunotherapy technology developed by Dr. Hooper and his colleagues. He serves on the editorial board of a number of journals including the Journal of Immunology and Scientific Reports and has been the recipient of numerous grants from the National Institutes of Health as well as other national and international agencies. Dr. Hooper received his doctorate in immunology from McGill University in Montreal, Quebec, Canada, and did his post-doctoral training at the University of Bristol, England.
Job Titles:
- Director
- Co - Founder of Bio - Path
- Director of Investor Relations
Douglas P. Morris is a co-founder of Bio-Path and a co-founding director. Mr. Morris has a number of administrative responsibilities, including working with retail broker/dealers in raising capital for small cap companies, and interfacing with existing shareholders. Mr. Morris has a Bachelor of Arts from Brigham Young University and is working towards a Master of Public Administration from the University of Southern California.
Job Titles:
- Scientific Co - Founder of Bio - Path Holdings
- Senior Vice President of Research, Development & Clinical Design
Dr. Ana Tari Ashizawa is a scientific co-founder of Bio-Path Holdings and serves as Senior Vice President of Research, Development & Clinical Design for the company. Dr. Tari Ashizawa is a leading expert in liposomes, and was instrumental in the development of Bio-Path's neutral lipid delivery technology. She was previously an associate professor at the University of Texas M.D. Anderson Cancer Center and the University of Florida, Gainesville. Dr. Tari Ashizawa holds a doctorate in biochemistry from the University of Tennessee, and a Master of Business Administration from the University of Florida.
Job Titles:
- Chairman
- Bio - Path 's Scientific Advisory Board As Its Chairman
Dr. Jorge Cortes joined Bio-Path's Scientific Advisory Board as its chairman and an inaugural member. A well-established expert in oncology and hematology, Dr. Cortes is currently the director of the Georgia Cancer Center. Over the course of his 25-year career specializing in leukemia research, Dr. Cortes has held several prestigious academic appointments at the University of Texas MD Anderson Cancer Center, including Jane and John Justin Distinguished Chair in Leukemia Research, chief of the AML (acute myeloid leukemia) and CML (chronic myelogenous leukemia) sections, and deputy chair of the Leukemia department.
Dr. Cortes has also lent his experience as a consultant to leading pharmaceutical companies such as AstraZeneca on the development of prenyltransferase inhibitors, GlaxoSmithKline on the use of topotecan in MDS (myelodysplastic syndromes) and CMML (chronic myelomonocytic leukemia), and Rhône-Poulenc Rorer (now Sanofi-Aventis) on the use of PEG-asparaginase in adult ALL (acute lymphoblastic leukemia).
Dr. Cortes earned his medical degree from la Facultad de Medicina, Universidad Nacional Autónoma de México and a Bachelor of Science from el Centro Universitario México. He currently serves on the National CML Society's Medical Advisory Board, as well as on numerous other executive committees and scientific advisory boards for organizations such as the Leukemia & Lymphoma Society and the International CML Foundation. He has over 230 grants and contracts where he was principal investigator. He has authored nearly 1,000 peer-review original research articles with numerous other accolades towards his name and practice.
Job Titles:
- Director
- Chief Financial Officer of Porto Energy Corp
Mr. Cleaver has served as chief financial officer of Porto Energy Corp., junior oil and gas exploration company listed on the Canadian Venture Exchange, since February 2011. Prior to his elevation to chief financial officer, Mr. Cleaver served as chief accounting officer. Mr. Cleaver served as corporate controller and then as vice president and chief accounting officer for BPZ Energy from October 2006 to mid-2010. Prior to joining BPZ, Mr. Cleaver was engaged as a consultant for a variety of public companies such as Rosetta Resources, Calpine Natural Gas and Index Oil and Gas. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor of Business Administration - Accounting from Texas A&M University.
Job Titles:
- Chairman
- Editor
- Program Director
Dr. Fleming is the chair and program director of the department of gastrointestinal oncology at Moffitt Cancer Center and a recognized leader in the treatment of gastrointestinal cancers. He initiated and developed the first direct xenograft program in gastrointestinal cancer at MD Anderson, providing a unique platform to examine pancreatic adenocarcinoma and to test new drug candidates for the treatment of pancreatic cancer. Prior to joining Moffitt, He was a professor in the department of surgical oncology at the University of Texas MD Anderson Cancer Center, where he served as chief of pancreas surgery and executive director of perioperative services.
Beyond his academic obligations, Dr. Fleming serves as an editor for numerous scientific journals including the Journal of Surgical Education, and serves on the editorial board of the Self-Assessment Program (SESAP) for the American College of Surgeons. During his career, he has written more than 130 peer-reviewed articles and 14 books. In addition, he has been recognized as a Castle Connolly Top Doctor since 2013 and included in the Consumer Research Council of America Guide to America's Top Surgeons since 2012.
Dr. Fleming received his M.D. from the University of Tennessee Center of Health Science. He completed his clinical residency in general surgery at the University of Texas Southwestern Medical Center, a fellowship at the University of Texas Southwestern Medical Center and a clinical fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center.
Job Titles:
- Director of Clinical Program Management
Michael Hickey has broad expertise in oncology and rare disease clinical drug development, especially focused on challenging indications such as head-and-neck cancer, colorectal cancer, breast cancer with BRCA mutations as well as program development for chemotherapy induced myelosuppression, hemophilia, and Battens Disease. At Bio-Path Holdings, Mr. Hickey will be responsible for development, implementation and oversight of the company's ongoing and planned trials. Mr. Hickey has held positions of increasing responsibility at Amgen, BioMarin, PPD and G1 Therapeutics, where he managed domestic and global drug development programs from their earliest clinical stages through regulatory submission. His experience in clinical development includes the regulatory approval of Brineura®, Kepivance®, and post-marketing development of Neupogen®/Neulasta®. In addition to his career activities, Mr. Hickey is a member of the Project Management Institute (PMI) and the Drug Information Association (DIA) the foremost professional organization in this field, responsible for setting standards for professional competence and promoting excellence in project management and drug development. Mr. Hickey earned his Bachelor of Science from the University of Southern California and an MBA from California State University at San Marcos.
Job Titles:
- Company 's Director of Manufacturing
- Director of Manufacturing Planning & Engineering
Michael Roberts is the company's Director of Manufacturing Planning and Engineering. He joined Bio-Path in September of 2014. Michael brings over 17 years of cGMP lipid manufacturing and liposomal formulation experience. He has worked with Bio-Path's leadership team on development projects for all of Bio-Path's pipeline drug products. Michael received his Bachelor of Science in chemical engineering from the University of Alabama in Huntsville.
Paul Aubert currently serves individuals and corporations through his private law practice. In addition, he serves as general counsel to four companies, including a developer of dental implant. Prior to launching his own practice, he served as general counsel of Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX), a specialty pharmaceutical company. For the 13 years prior to joining Pernix, Mr. Aubert worked in the Corporate and Securities divisions of several law firms, including Weil, Gotshal & Manges and Andrews Kurth LLP, and Winstead PC, where he provided legal advice on general corporate matters as well as securities and M&A transactions to public and private companies. He received his Juris Doctor and MBA from Tulane University in New Orleans, Louisiana in 1996, and his Bachelor of Arts in history from Louisiana State University - Baton Rouge in 1990.
Job Titles:
- Chief Executive Officer
- Chief Financial Officer
Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path's President, Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors. At the time of Bio-Path's establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas M.D. Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path's lead product, BP1001. Over the next ten years, Mr. Nielsen led the clinical advancement of BP1001 into Phase 2 studies, the introduction of additional pipeline candidates, and the company's public market debut. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path and of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department, and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley.